Production (Stage)
Appili Therapeutics Inc.
APLIF
$0.0137
$0.001916.10%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -88.23% | -89.47% | -27.06% | 147.59% | 147.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.23% | -89.47% | -27.06% | 147.59% | 147.59% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -88.23% | -89.47% | -27.06% | 147.59% | 147.59% |
| SG&A Expenses | -15.11% | -24.13% | -34.74% | -34.47% | -30.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.35% | 10.41% | 13.19% | 11.13% | 5.89% |
| Operating Income | -21.55% | -24.98% | -16.43% | -5.52% | -0.03% |
| Income Before Tax | 30.92% | 25.92% | 54.06% | 55.80% | 60.28% |
| Income Tax Expenses | -74.66% | -99.20% | -83.05% | 51.97% | 92.19% |
| Earnings from Continuing Operations | 31.74% | 26.85% | 54.41% | 55.32% | 59.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.74% | 26.85% | 54.41% | 55.32% | 59.69% |
| EBIT | -21.55% | -24.98% | -16.43% | -5.52% | -0.03% |
| EBITDA | -21.60% | -25.00% | -16.41% | -5.46% | 0.07% |
| EPS Basic | 31.17% | 26.69% | 54.41% | 55.38% | 63.04% |
| Normalized Basic EPS | 30.77% | 23.86% | 52.94% | 54.72% | 62.66% |
| EPS Diluted | 31.17% | 26.69% | 54.41% | 55.38% | 63.04% |
| Normalized Diluted EPS | 30.77% | 23.86% | 52.94% | 54.72% | 62.66% |
| Average Basic Shares Outstanding | 0.00% | 0.03% | 0.03% | 0.03% | 6.68% |
| Average Diluted Shares Outstanding | 0.00% | 0.03% | 0.03% | 0.03% | 6.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |